Health Care · Services-Home Health Care Services · Nasdaq · CIK 1865782 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $72.88Day +5.06%Mkt cap $14.1BP/E (FY) 83.8×1Y +242.0%Off 52W high −1.2%Vol (1Y) 40.7%
Daily closing price, split-adjusted to the current basis; 2.5y shown of 623 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesNEVER-OBSERVED · 42.4% growth |
| Short interest5.1% of sh out |
| Days to cover3.4d |
| 13F net flow (QoQ)−3.32% |
| Top-10 13F concentration64.9% |
| Next report (est.)2026-07-31 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)83.8× |
| Sales (TTM)$13.65B |
| Earnings (TTM)$309.9M |
| ROE10.8% |
| Net margin1.5% |
| ROIC5.3% |
| YTD+94.6% |
| 1Y+242.0% |
| Since incept. (ann.)+112.5% |
Total return through 2026-07-30 · series begins 2024-01-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)40.7% |
| Ann. volatility (3Y)43.7% |
| Sharpe (1Y)3.45 |
| Sharpe (3Y)1.97 |
| Max drawdown (1Y)−9.3% |
| Max drawdown (3Y)−35.6% |
| Beta (3Y vs SPY)1.78 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 41.8M | $1.8B | 21.61% | −32.5% |
| FMR LLC | 21.0M | $894M | 10.84% | −7.5% |
| BlackRock, Inc. | 19.6M | $835M | 10.13% | +15.4% |
| Invesco Ltd. | 11.5M | $489M | 5.93% | +8.4% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 10.7M | $455M | 5.52% | +0.1% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8.0M | $342M | 4.15% | new |
| T. Rowe Price Investment Management, Inc. | 7.6M | $325M | 3.94% | +6.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.3M | $268M | 3.25% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 108.1% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 14,048,828 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-01 | $0.67 | +378.6% | $3.61B | +25.6% |
| 2025-12-31 | 2026-02-27 | — | — | $3.55B | +29.3% |
| 2025-09-30 | 2025-10-28 | $0.26 | — | $3.33B | +14.7% |
| 2025-06-30 | 2025-08-01 | $0.13 | +30.0% | $3.15B | +15.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-07-31 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Pharmacy Solutions 89% · Provider Services 11%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Debt / equity1.34× |
| Total debt / EBITDA5.46× |
| Sales growth 3Y18.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
